Aileron Therapeutics

$1.52
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-3.18%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ALRN and other stocks, options, and ETFs commission-free!

About ALRN

Aileron Therapeutics, Inc. Common Stock, also called Aileron Therapeutics, is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA. The listed name for ALRN is Aileron Therapeutics, Inc. Common Stock.

CEO
Manuel C. Aivado
Employees
13
Headquarters
Watertown, Massachusetts
Founded
2005
Market Cap
131.13M
Price-Earnings Ratio
Dividend Yield
Average Volume
2.61M
High Today
$1.60
Low Today
$1.47
Open Price
$1.53
Volume
1.30M
52 Week High
$2.47
52 Week Low
$0.25

ALRN Earnings

-$0.28
-$0.19
-$0.09
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 30, After Hours

You May Also Like

NCB
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure